“This event focuses on the rapidly growing use of digital signatures across all applications in a life science organization,”
There are many forms of electronic signatures that can comply with FDA 21 CFR Part 11. However, only standards-based digital signatures enable the benefits of digital signatures to extend beyond pure compliance requirements and facilitate accelerated decision making, expedited approval processes, operational cost reductions, and more efficient and paperless operations both inside an organization and externally in B2B or electronic submission applications.
During the DIA event, Mr. Schlerf and other industry thought leaders from biopharmaceutical companies, CROs, and technology providers will discuss strategies that facilitate the adoption of digital signatures for organizations of every size. Moreover, case studies will be provided from organizations that have successfully implemented digital signature applications for processes including internal quality and clinical operations, large web-based business-to-
About ARX (Algorithmic Research)
ARX has over 20 years of experience assisting life sciences, healthcare, governmental, engineering, banking, financial services organizations and commercial sectors to secure and streamline their business processes and transactions. ARX offers a wide range of highly scalable products designed to simplify, secure, and accelerate electronic business. For more information, please visit http://www.arx.com
